At the presentation of Pharming Group N.V.’s financial report for the first quarter of the year ended 31 March 2020 CEO Sijmen de Vries says:
“We received EMA and FDA approval of our new production facility for Ruconest, which will double our production capacity once fully operational later this year. In addition, approval from the European Commission to treat acute HAE attacks in children with Ruconest allows us to serve the most vulnerable patients and further demonstrates the safety and efficacy of our lead product. In addition to these achievements, Pharming has continued to deliver strong sales growth as new patients continue to benefit from Ruconest’s product profile. Following the reacquisition of Ruconest-licensed territories from January 2020, we are excited to expand our distribution network in Europe, where we are seeing increasing demand for the product.”
(Source: Pharming)
